Most bought healthcare stocks in Q2 2024
See which Healthcare stocks institutional investors increased the most in Q2 2024, measured as net growth in reported share positions from Q1 2024 into Q2 2024. Notable additions at the top of this list include CVS HEALTH CORP (CVS), HUMANA INC (HUM), SOLVENTUM CORP (SOLV), BAXTER INTERNATIONAL INC (BAX). These rankings are based on SEC 13F filings from the investors we track.
Explore more:
| Symbol | Name | Net shares | Net value | New | Added | Trimmed | Sold out | Holding now |
|---|---|---|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 29,460,741 | $716.19M | 1 | 6 | 4 | 1 | 11 |
| HUM | HUMANA INC | 8,601,526 | $3.16B | 2 | 3 | 2 | 1 | 7 |
| SOLV | SOLVENTUM CORP | 7,237,002 | $286.55M | 5 | 0 | 0 | 0 | 5 |
| BAX | BAXTER INTERNATIONAL INC | 5,881,595 | -$310.47M | 0 | 4 | 3 | 1 | 8 |
| ALHC | ALIGNMENT HEALTHCARE INC | 4,205,949 | $43.37M | 1 | 1 | 0 | 0 | 2 |
| PFE | PFIZER INC | 3,620,477 | $215.81M | 1 | 5 | 8 | 0 | 15 |
| RXRX | RECURSION PHARMACEUTICALS-A | 3,555,357 | -$34.07M | 0 | 1 | 0 | 0 | 1 |
| TXG | 10X GENOMICS INC-CLASS A | 3,187,751 | -$50.59M | 0 | 2 | 0 | 0 | 2 |
| WRBY | WARBY PARKER INC-CLASS A | 3,172,998 | $79.75M | 1 | 2 | 1 | 0 | 4 |
| XRAY | DENTSPLY SIRONA INC | 3,153,470 | $12.73M | 0 | 2 | 1 | 0 | 3 |
| UNH | UNITEDHEALTH GROUP INC | 3,017,638 | $1.72B | 4 | 11 | 11 | 0 | 28 |
| FTRE | FORTREA HOLDINGS INC | 2,805,977 | $4.62M | 0 | 2 | 1 | 1 | 3 |
| AVTR | AVANTOR INC | 2,573,245 | -$274.93M | 1 | 2 | 3 | 0 | 6 |
| HLN | HALEON PLC-ADR | 2,459,514 | -$1.69M | 0 | 3 | 3 | 0 | 6 |
| ABSI | ABSCI CORP | 2,096,494 | -$1.66M | 0 | 1 | 0 | 1 | 1 |
| BMY | BRISTOL-MYERS SQUIBB CO | 2,038,808 | -$301.66M | 2 | 2 | 5 | 1 | 11 |
| DOCS | DOXIMITY INC-CLASS A | 2,003,400 | $97.32M | 0 | 2 | 1 | 0 | 3 |
| LFST | LIFESTANCE HEALTH GROUP INC | 1,934,423 | -$2.27M | 0 | 1 | 1 | 0 | 2 |
| NVST | ENVISTA HOLDINGS CORP | 1,887,576 | -$4.48M | 0 | 2 | 1 | 0 | 3 |
| INBX | INHIBRX BIOSCIENCES INC | 1,787,705 | $25.33M | 1 | 0 | 0 | 0 | 1 |
| IRWD | IRONWOOD PHARMACEUTICALS INC | 1,574,097 | $54.30M | 0 | 2 | 0 | 0 | 2 |
| SGMO | SANGAMO THERAPEUTICS INC | 1,528,600 | $1.48M | 0 | 1 | 0 | 0 | 1 |
| ACHC | ACADIA HEALTHCARE CO INC | 1,518,022 | $54.74M | 0 | 3 | 0 | 0 | 3 |
| CRBU | CARIBOU BIOSCIENCES INC | 1,482,900 | $2.43M | 1 | 0 | 0 | 0 | 1 |
| GOSS | GOSSAMER BIO INC | 1,395,000 | $1.84M | 0 | 2 | 0 | 0 | 2 |
| ALLO | ALLOGENE THERAPEUTICS INC | 1,351,055 | $4.07M | 0 | 1 | 0 | 0 | 1 |
| BAYRY | BAYER AG-SPONSORED ADR | 1,275,315 | $7.06M | 0 | 1 | 0 | 0 | 1 |
| NVAX | NOVAVAX INC | 1,110,183 | $14.05M | 1 | 0 | 0 | 0 | 1 |
| ADPT | ADAPTIVE BIOTECHNOLOGIES | 949,921 | $20.26M | 0 | 2 | 0 | 0 | 3 |
| INSM | INSMED INC | 901,983 | $69.41M | 1 | 0 | 0 | 1 | 1 |
| BDX | BECTON DICKINSON AND CO | 844,182 | $242.58M | 0 | 4 | 3 | 0 | 9 |
| AUTL | AUTOLUS THERAPEUTICS PLC | 821,156 | $3.98M | 0 | 1 | 0 | 0 | 1 |
| GERN | GERON CORP | 781,723 | $3.31M | 1 | 0 | 0 | 0 | 1 |
| EVH | EVOLENT HEALTH INC - A | 769,801 | -$28.33M | 0 | 1 | 0 | 1 | 1 |
| BIO | BIO-RAD LABORATORIES-A | 727,826 | $151.78M | 0 | 4 | 1 | 0 | 5 |
| VREX | VAREX IMAGING CORP | 707,204 | $7.33M | 0 | 2 | 1 | 0 | 3 |
| GLYC | GLYCOMIMETICS INC | 685,151 | $232.42K | 0 | 1 | 0 | 0 | 1 |
| ZBH | ZIMMER BIOMET HOLDINGS INC | 683,483 | -$339.72M | 1 | 5 | 4 | 0 | 10 |
| ITGR | INTEGER HOLDINGS CORP | 683,380 | $78.75M | 0 | 1 | 0 | 0 | 1 |
| MRVI | MARAVAI LIFESCIENCES HLDGS-A | 668,552 | $27.76M | 0 | 1 | 0 | 0 | 1 |
| NTLA | INTELLIA THERAPEUTICS INC | 645,207 | -$41.94M | 1 | 1 | 0 | 0 | 2 |
| LH | LABCORP HOLDINGS INC | 633,162 | $128.85M | 5 | 0 | 0 | 0 | 5 |
| MRNS | MARINUS PHARMACEUTICALS INC | 621,625 | $727.30K | 1 | 0 | 0 | 0 | 1 |
| LBPH | LONGBOARD PHARMACEUTICALS IN | 606,234 | $23.64M | 0 | 1 | 0 | 1 | 1 |
| ADMA | ADMA BIOLOGICS INC | 575,100 | $28.86M | 0 | 1 | 0 | 0 | 1 |
| IMVT | IMMUNOVANT INC | 560,130 | $13.05M | 0 | 2 | 0 | 0 | 2 |
| FATE | FATE THERAPEUTICS INC | 548,544 | $1.80M | 1 | 0 | 0 | 0 | 1 |
| OSCR | OSCAR HEALTH INC - CLASS A | 545,959 | $64.59M | 0 | 2 | 2 | 0 | 4 |
| HUMA | HUMACYTE INC | 524,600 | $2.88M | 0 | 1 | 0 | 0 | 1 |
| TEM | TEMPUS AI INC | 522,698 | $18.29M | 1 | 0 | 0 | 0 | 1 |
Frequently asked questions about Most bought healthcare stocks in Q2 2024
What are the most bought Healthcare stocks in Q2 2024?
The most bought healthcare stocks in Q2 2024 are those with the largest increase in reported share counts across tracked institutional investors compared to Q1 2024, based on SEC 13F filings.
Which healthcare stocks did institutional investors added to the most in Q2 2024?
Among the managers we track, net additions were largest in companies such as CVS HEALTH CORP (CVS), HUMANA INC (HUM), SOLVENTUM CORP (SOLV), based on aggregated 13F data.
How is institutional buying calculated?
Buying is calculated by summing the net increase in shares reported by tracked investors between two consecutive quarterly 13F snapshots (compared to Q1 2024).
Does this include all institutional owners?
These rankings are based on a subset of tracked institutional investors who file SEC 13F reports. While not exhaustive, the dataset includes many of the largest and most influential funds.
Are these trades real-time?
No. 13F filings are reported quarterly and may be delayed by up to 45 days. The data reflects positions at the end of the reporting period, not real-time trading activity.